Liver transplant drug showdown: which lowers pressure better?
NCT ID NCT07304466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, terlipressin and somatostatin, to see which one better lowers high blood pressure in the liver's main vein during a living-donor liver transplant. High pressure can cause dangerous bleeding, so finding the best drug may improve safety. About 50 adults with severe liver disease and high portal pressure will receive one of the drugs during surgery and be monitored for 7 days after.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istanbul Medipol University Medipol Mega Hospital
RECRUITINGIstanbul, Bagcilar, 34218, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can extra doses of an old drug reverse liver scarring?
- A new Anti-Rejection strategy may spare kidney function after liver transplant
- Can a cell test free liver transplant patients from lifelong drugs?
- Smartphone messages may boost medication adherence after liver transplant
- Could the Body's largest vein replace a Hard-to-Reach one for liver pressure checks?
- Blood type no barrier? study tests liver transplant success across ABO barriers